| Literature DB >> 21794159 |
Jing Sun1, Tao Jiang, Zhengjun Qiu, Gang Cen, Jun Cao, Kejian Huang, Ying Pu, Hong Liang, Renxiang Huang, Shifu Chen.
Abstract
BACKGROUND: Laparoscopic procedure is a rapid developed technique in colorectal surgery. In this investigation we aim at assessing the diversities of short-term and medium-term clinical outcomes of laparoscopic-assisted versus open surgery for colorectal cancer.Entities:
Mesh:
Year: 2011 PMID: 21794159 PMCID: PMC3160957 DOI: 10.1186/1471-230X-11-85
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Demographic Data and Intraoperative Data
| LAP (n = 254) | OP (n = 265) | P | ||||
|---|---|---|---|---|---|---|
| n | % | n | % | |||
| Age (Years, mean ± SD) | 67.5 ± 10.8 | 66.0 ± 12.1 | 0.137 | |||
| Gender | Male | 138 | 54.3 | 126 | 47.5 | 0.136 |
| Female | 116 | 45.7 | 139 | 52.5 | ||
| BMI (kg/m2, mean ± SD) | 23.4 ± 4.1 | 23.5 ± 3.9 | 0.622 | |||
| ASA Score | 1 | 17 | 6.7 | 27 | 10.2 | 0.222 |
| 2 | 148 | 58.3 | 160 | 60.4 | ||
| 3 | 83 | 32.7 | 69 | 26.1 | ||
| 4 | 6 | 2.3 | 9 | 3.3 | ||
| Abdominal Operation History | 1.000 | |||||
| No | 194 | 76.4 | 202 | 76.2 | ||
| Yes | 60 | 23.6 | 63 | 23.8 | ||
| Preoperative Comorbid Diseases | 0.333 | |||||
| No | 109 | 42.9 | 125 | 47.2 | ||
| Yes | 145 | 57.1 | 140 | 52.8 | ||
| Cardiovascular | 113 | 111 | ||||
| Respiratory | 10 | 11 | ||||
| Hepatic Cirrhosis | 0 | 1 | ||||
| Renal Failure | 4 | 6 | ||||
| Cerebral Infarction | 7 | 8 | ||||
| Diabetes | 39 | 30 | ||||
| Autoimmunal | 1 | 1 | ||||
| Others | 17 | 15 | ||||
| Intervention | Right Colectomy | 70 | 27.6 | 72 | 27.2 | 0.906 |
| Transverse Colectomy | 3 | 1.2 | 6 | 2.2 | ||
| Left Colectomy | 16 | 6.2 | 15 | 5.7 | ||
| Sigmoidectomy | 67 | 26.4 | 68 | 25.7 | ||
| HAR | 51 | 20.1 | 56 | 21.1 | ||
| LAR | 17 | 6.7 | 26 | 9.8 | ||
| APR | 27 | 10.6 | 19 | 7.2 | ||
| Hartmann | 1 | 0.4 | 3 | 1.1 | ||
| Bacon | 2 | 0.8 | 0 | 0.0 | ||
| Conversions to Opena | 8 | 3 | / | / | ||
| Operative Time (min, mean ± SD) | 135.6 ± 40.0 | 131.2 ± 46.0 | 0.307 | |||
| Blood Loss (ml, mean ± SD) | 101.5 ± 70.8 | 104.7 ± 118.8 | 0.002 | |||
| Maximum Incision (cm, mean ± SD) | 4.3 ± 1.1 | 13.6 ± 2.3 | 0.000 | |||
BMI, Body Mass Index; ASA, American Society of Anesthesiologists; HAR, High Anterior Resection; LAR, Low Anterior Resection; APR, Abdomioperineal Resection; a, 1 HAR, 1 LAR, 1 Sigmoid Colostomy, 2 Right Colectomy, and 3 Sigmoidectomy; All conversions on account of severe local invasion and adhesion (Excluded from Laparoscopic group)
Pathological Parameters
| LAP (n = 254) | OP (n = 265) | P | ||||
|---|---|---|---|---|---|---|
| n | % | n | % | |||
| Location | Right-hemi Colon | 70 | 27.6 | 72 | 27.2 | 0.896 |
| Transverse Colon | 3 | 1.2 | 6 | 2.2 | ||
| Left-hemi Colon | 16 | 6.2 | 15 | 5.7 | ||
| Sigmoid Colon | 65 | 25.6 | 68 | 25.7 | ||
| Rectum | 100 | 39.4 | 104 | 39.2 | ||
| Tumor Size (cm, mean ± SD) | 4.7 ± 1.7 | 4.8 ± 1.9 | 0.579 | |||
| Proximal Margin for colon cancer (cm)a | 12.7 ± 6.8 | 11.4 ± 4.1 | 0.000 | |||
| Distal Margin for colon cancer (cm)a | 10.7 ± 6.7 | 9.8 ± 5.7 | 0.189 | |||
| Proximal Margin for rectum cancer (cm)b | 11.4 ± 4.3 | 11.7 ± 4.7 | 0.573 | |||
| Distal Margin f for rectum cancer(cm)b | 4.8 ± 3.1 | 4.0 ± 1.7 | 0.052 | |||
| Total Sample Length(cm) | 26.3 ± 10.5 | 25.4 ± 8.9 | 0.302 | |||
| Lymph Nodes Retrieved | 12.0 ± 6.9 | 11.4 ± 7.1 | 0.327 | |||
| Pathological Results | ||||||
| Differentiation | 0.222 | |||||
| Well-differentiated | 51 | 20.1 | 53 | 20.0 | ||
| Moderate-differentiated | 172 | 67.7 | 166 | 62.6 | ||
| Poor-differentiated | 16 | 6.3 | 17 | 6.5 | ||
| Mucinous | 15 | 5.9 | 29 | 10.9 | ||
| pT | 0.362 | |||||
| pT1 | 33 | 13.0 | 27 | 10.2 | ||
| pT2 | 63 | 24.8 | 52 | 19.6 | ||
| pT3 | 75 | 29.5 | 107 | 40.4 | ||
| pT4 | 83 | 32.7 | 79 | 29.8 | ||
| pN | 0.661 | |||||
| pN0 | 104 | 40.9 | 117 | 44.2 | ||
| pN1 | 83 | 32.7 | 81 | 30.6 | ||
| pN2 | 67 | 26.4 | 67 | 25.3 | ||
| Lymph Nodes Metastasis | 0.478 | |||||
| Yes | 150 | 59.1 | 148 | 55.8 | ||
| No | 104 | 40.9 | 117 | 44.2 | ||
| TMN Stage | 0.286 | |||||
| I | 26 | 10.2 | 17 | 6.4 | ||
| II | 103 | 40.6 | 111 | 41.9 | ||
| III | 125 | 49.2 | 137 | 51.6 | ||
aLaparoscopy group n = 154, open group n = 161.
bLaparoscopy group n = 100, open group n = 104.
Perioperative Complications for Colorectal Cancer
| LAP (n = 254) | OP (n = 265) | P | |||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Intraoperative Complications | 6 | 2.4 | 3 | 1.1 | 0.330 |
| Massive Hemorrhage (> 1000 ml) | 1 | 1 | |||
| Organ Injury | 2 | 1 | |||
| Equipment Disorders | 2 | 0 | |||
| Others | 1a | 1b | |||
| Post-operative Complications | 33 | 12.9 | 34 | 12.8 | 0.530 |
| Ileus | 6 | 5 | |||
| Anastomotic Hemorrhage | 1 | 0 | |||
| Abdominal Hemorrhage | 1 | 1 | |||
| Peritonitis/Septic Shock | 1 | 1 | |||
| Anastomotic Leakage | 5 | 4 | |||
| Pelvic Abscess | 2 | 3 | |||
| Wound Infection | 5 | 6 | |||
| Incisional/Port Herniation | 3 | 2 | |||
| Cardiovascular Disorders | 1 | 3 | |||
| Respiratory Disorders | 0 | 3 | |||
| Renal Failure | 0 | 2 | |||
| Urinary Infection | 2 | 1 | |||
| Cerebral Disorders | 1 | 1 | |||
| Colostomy Stoma | 1 | 0 | |||
| Others | 4c | 2d | |||
| Re-operative cases | 7e | 2.8 | 3f | 1.1 | 0.213 |
a 1 of Subcutaneous Emphysema.
b 1 of stapler leakage during LAR.
c 1 of Lymphatic Fistula, 1 of Deep Vein Thrombosis, 1 of Common Peroneal Nerve Injury, 1 of Pneumoperitoneum-related Acidosis.
d 1 of Urinary Retention, 1 of Recto-vaginal Fistula.
e 1 Re-colostomy for Colostomy Stoma Necrosis, 1 Hartmann for Anastomotic Hemorrhage, 1 Laparotomy for Anastomotic Obstruction, 1 Hartmann for Leakage, 3 Transverse Colostomies for Leakage.
f 1 Abscess Drainage for Pelvic-perianal Abscess, 1 Transverse Colostomy for Leakage, 1 Reconstruction for Recto-vaginal Fistula.
Postoperative Recovery
| LAP (n = 254) | OP(n = 265) | P | |||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Analgesic Usage | 0.000 | ||||
| No | 168 | 66.1 | 52 | 19.6 | |
| Short-acting Drug | 34 | 13.4 | 18 | 6.8 | |
| PCIA | 52 | 20.5 | 195 | 73.6 | |
| VAS Score (NRS) on POD#1 (mean ± SD) | 2.8 ± 1.6 | 3.2 ± 1.9 | 0.008 | ||
| Off-bed (day, mean ± SD) | 2.8 ± 1.8 | 4.7 ± 3.1 | 0.000 | ||
| Peristalsis Recovery (day, mean ± SD) | 1.8 ± 0.8 | 2.5 ± 1.2 | 0.000 | ||
| Flatus (day, mean ± SD) | 3.2 ± 1.6 | 4.3 ± 2.9 | 0.000 | ||
| Liquid Intake (day, mean ± SD) | 3.6 ± 2.1 | 5.3 ± 4.3 | 0.000 | ||
| Semi-liquid Intake (day, mean ± SD) | 6.1 ± 2.5 | 8.2 ± 4.7 | 0.000 | ||
| Post-op Hospital Stay (day, mean ± SD) | 9.8 ± 4.7 | 13.1 ± .7.2 | 0.000 | ||
| Total Hospital Stay (day, mean ± SD) | 17.6 ± 7.4 | 22.9 ± 9.3 | 0.000 | ||
PCIA, Patient Controlled Intravenous Analgesia, personalized prescription of tramadol and fentanyl. VAS, Visual Analog Scales; NRS, Numerical Rating Scales.
Postoperative Recurrence and Survival for Colorectal Cancer
| Colon Cancer | P | Rectal Cancer | P | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| LAP (n = 154) | OP(n = 161) | LAP (n = 100) | OP(n = 104) | |||||||
| n | % | n | % | n | % | n | % | |||
| Overall Mortality | 33 | 21.4 | 45 | 28.0 | 0.113 | 25 | 25.0 | 29 | 27.9 | 0.439 |
| Cause of Death | ||||||||||
| Peri-operative Mortality | 1a | 1c | 1b | 1c | ||||||
| Tumor Progression | 31 | 42 | 22 | 27 | ||||||
| Others | 1d | 2e | 2f | 1g | ||||||
| Tumor Recurrence | 44 | 28.6 | 47 | 29.2 | 0.501 | 33 | 33.0 | 32 | 30.8 | 0.482 |
| Type of Recurrence | ||||||||||
| Locoregional Relapse | 18 | 21 | 17 | 18 | ||||||
| Metastasis | 24 | 25 | 15 | 14 | ||||||
| Incision/Port Metastasis | 2 | 1 | 1 | 0 | ||||||
a 1 on POD#19 for septic shock (Excluded from Laparoscopic group for survival analysis).
b 1on POD#1 for cardiac arrest (Excluded from Laparoscopic group for survival analysis).
c 2 on POD#6, POD#7 respectively for cardiovascular accident (Excluded from Open group).
d 1 for traffic accident.
e 1 for unknown reason, 1 for cardiac infarction.
f 1for cerebral hemorrhage, 1 for cardiac infarction.
g 1 for cardiac infarction.
Figure 1Survival Analysis in Colon Cancer Cases. The laparoscopic-assisted group is represented by a continuous line and the open surgery group is represented by a dotted line. The red lines represent overall survival for all stages in the two groups (P = 0.305). The green lines represent overall survival for stage I-II patients in the two groups (P = 0.498). The blue lines represent overall survival for stage III patients in the two groups (P = 0.629).
Figure 2Survival Analysis in Rectal Cancer Cases. The laparoscopic-assisted group is represented by a continuous line and the open surgery group is represented by a dotted line. The red lines represent overall survival for all stages in the two groups (P = 0.954). The green lines represent overall survival for stage I-II patients in the two groups (P = 0.723). The blue lines represent overall survival for stage III patients in the two groups (P = 0.949).
Figure 3Cancer-free Survival Analysis in Colon Cancer Cases. The laparoscopic-assisted group is represented by a continuous line and the open surgery group is represented by a dotted line. The cancer-free survival for all colon cancer cases in the two groups have no significant difference (P = 0.973).
Figure 4Cancer-free Survival Analysis in Rectal Cancer Cases. The laparoscopic-assisted group is represented by a continuous line and the open surgery group is represented by a dotted line. The cancer-free survival for all rectal cancer cases in the two groups have no significant difference (P = 0.968).
Univariate Risk Evaluations for Recurrence and Survival
| Factors | Over-all Death Risk (n = 519) | Recurrence Risk (n = 519) | ||
|---|---|---|---|---|
| Chi2 | P | Chi2 | P | |
| Gender | 0.847 | 0.357 | 0.270 | 0.604 |
| Age (years,≤65, > 65) | 2.642 | 0.104 | 2.398 | 0.122 |
| BMI (kg/m2, ≤24, > 24) | 0.451 | 0.502 | 0.128 | 0.721 |
| ASA Score | 1.675 | 0.642 | 2.996 | 0.392 |
| Pre-op Comorbidities | 2.460 | 0.117 | 1.672 | 0.196 |
| Tumor Location | 8.726 | 0.068 | 6.570 | 0.160 |
| Intervention | 12.510 | 0.085 | 8.843 | 0.264 |
| Surgical Procedures | 0.588 | 0.443 | 0.002 | 0.968 |
| Tumor Diameter (cm, ≤5, > 5) | 2.279 | 0.133 | 4.040 | 0.044 |
| pT | 1.616 | 0.656 | 11.776 | 0.008 |
| pN | 14.476 | 0.001 | 9.615 | 0.008 |
| Pathological Differentiation | 1.565 | 0.667 | 1.808 | 0.613 |
| Lymph Node Metastasis | 14.714 | 0.000 | 9.811 | 0.002 |
| Clinical Stage | 32.953 | 0.000 | 24.848 | 0.000 |
| Post-op Complications | 0.689 | 0.407 | 0.220 | 0.639 |
Multivariable Risk Evaluation for Recurrence and Survival
| Factors | Over-all Death Risk (n = 519) | Recurrence Risk (n = 519) | ||||
|---|---|---|---|---|---|---|
| Chi2 | HR (95%CI) | P | Chi2 | HR (95%CI) | P | |
| Gender | -0.236 | 0.790 (0.554-1.125) | 0.191 | -0.136 | 0.873 (0.629-1.213) | 0.418 |
| Age | 0.446 | 1.813 (0.976-4.045) | 0.047 | 0.216 | 1.241 (0.883-1.745) | 0.213 |
| BMI | -0.243 | 0.784 (0.549-1.120) | 0.181 | -0.125 | 0.882 (0.635-1.227) | 0.456 |
| ASA Score | 0.236 | 1.267 (0.965-1.663) | 0.089 | 0.091 | 1.095 (0.851-1.409) | 0.481 |
| Pre-op Comorbidities | 0.173 | 1.189 (0.822-1.720) | 0.359 | 0.107 | 1.113 (0.791-1.565) | 0.540 |
| Tumor Location | -0.088 | 0.916 (0.809-1.036) | 0.161 | -0.062 | 0.939 (0.840-1.051) | 0.275 |
| Intervention | -0.049 | 0.952 (0.871-1.041) | 0.279 | -0.030 | 0.971 (0.893-1.055) | 0.485 |
| Surgical Procedures | 0.175 | 1.192 (0.833-1.706) | 0.338 | 0.018 | 1.018 (0.732-1.416) | 0.914 |
| Tumor Diameter | 0.212 | 1.236 (0.858-1.781) | 0.255 | 0.280 | 1.324 (0.944-1.856) | 0.104 |
| pT | 0.536 | 1.965 (0.807-12.153) | 0.049 | 0.632 | 1.533 (0.874-10.220) | 0.023 |
| pN | 0.513 | 1.713 (0.647-11.584) | 0.056 | 0.576 | 1.913 (0.665-13.544) | 0.015 |
| Pathological Differentiation | -0.172 | 0.842 (0.659-1.077) | 0.171 | -0.154 | 0.857 (0.683-1.075) | 0.182 |
| Lymph Node Metastasis | 0.763 | 9.757 (2.186-43.546) | 0.003 | 8.280 | 20.074 (2.602-154.853) | 0.005 |
| Clinical Stage | 1.354 | 3.875 (2.343-6.407) | 0.000 | 1.031 | 2.803 (1.788-4.396) | 0.000 |
| Post-op Complications | -0.309 | 0.734 (0.386-1.395) | 0.345 | -0.173 | 0.841 (0.476-1.488) | 0.552 |
95% CI, 95% Confidence Interval